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In this issue of Cell Stem Cell, Martı´nez-Cerden˜o and colleagues (2010) transplant interneuron precursors
from the MGE into the striatum of a rat model of Parkinson’s disease and observe a 5% increase in the
endogenous GABAergic interneuron population resulting in behavioral benefits in both lesioned and wild-
type animals.One in eight hundred individuals in the
Western world suffers from Parkinson’s
disease (PD), which predominantly results
from dysfunction in dopaminergic, neuro-
melanin-containing cells of the substantia
nigra pars compacta (SNc). Although
dopaminergic cells are disproportionately
affected in PD, the syndrome more gen-
erally results in dysregulation of the
processing of information by the basal
ganglia. In recent years, direct treatment
of PD has been attempted with transplan-
tations to restore dopamine levels. The
first human trials with adrenal chromaffin
cells, which produce and release sub-
stantial quantities of catecholamines,
gave promising, but unfortunately not
very reproducible, results (Drucker-Colin
and Verdugo-Diaz, 2004; Freed et al.,
1981). Others have decided to strike the
problem at its core by transplanting
embryonic or partially differentiated SNc
cells in different brain regions (Bjorklund
and Stenevi, 1979). For this approach to
succeed, axons from the transplanted
cells need to find their way to the striatum
where dopamine exerts its action on both
GABAergic medium spiny projection
neurons and interneurons. To overcome
this challenge, an alternative approach is
to transplant the dopamine neuronal
precursor cells directly into the striatum
(Freeman et al., 1995; Lindvall et al.,
1994).
In this issue, Martı´nez-Cerden˜o et al.
(2010) undertook a variation on this
approach in an attempt to restore some of
the motor deficits observed in 6-OHDA
(6-hydroxydopamine) SNc-lesioned ani-
mals, a widely used model of PD. Instead
of trying to restore dopamine levels by184 Cell Stem Cell 6, March 5, 2010 ª2010 Eintroducing new dopaminergic neurons,
the authors transplanted GABAergic
precursor cells into the striatum. Fore-
brain GABAergic cells have been shown
to originate embryonically from the gan-
glionic eminences of the ventral telen-
cephalon, which based on anatomical
and gene expression criteria have been
subdivided into three anlagen, the medial,
lateral, and caudal ganglionic eminences
(MGE, LGE, and CGE, respectively)
(Batista-Brito and Fishell, 2009). Of these
regions, the MGE is known to produce
a large percentage of striatal GABAergic
interneurons, which have the remarkable
ability to migrate widely even after
transplantation within the postnatal fore-
brain (Wichterle et al., 1999). Therefore,
although the idea of introducing inhibitory
GABAergic neurons may seem counterin-
tuitive, if one thinks of PD as a network
dysfunction (DeLong and Wichmann,
2007), the new methodology is highly
intriguing.
In testing the inhibitory approach, Mar-
tı´nez-Cerden˜o et al. (2010) dissected out
MGE-derived precursor cells from E14.5
rat brains and transplanted them into the
striatum of the 6-OHDA-lesioned rats.
Although 25% of the cells within these
grafts differentiated into oligodendro-
cytes, the remainder became neurons.
Remarkably, MGE grafts directed into
the striatum produce no astrocytes,
despite the observation by the authors
that the same cells transplanted into the
subthalamic nuclei gives rise solely to
astrocytes. Moreover, although only 1%
of the grafted cells survived in the striatum
after 1 year, those present differentiated
into morphologically and electrophysio-lsevier Inc.logically mature interneurons of the three
major subtypes found in the striatum,
namely CR+, PV+, and SOM+ cells (Tepper
and Bolam, 2004), all of which have been
shown to originate from the MGE at
embryonic stages. Evenmore remarkably,
even though the surviving transplanted
interneurons accounted for only about
5% of the total endogenous GABAergic
interneuron population, they were suffi-
cient to provide functional recovery in the
lesioned animals, as assessed by behav-
ioral and motor activity. The authors
show that the interneurons integrated
into the host circuitry by receiving and
forming de novo synapses and hence
they hypothesize that it is the transplant-
mediated reorganization of the basal
ganglia network that directly results in
the functional recovery observed. By
contrast, when the same donor cells
were transplanted into the subthalamic
nuclei, they failed to disperse, produce
neurons, or provide therapeutic improve-
ment of PD-like symptoms.
Why would MGE transplants into the
striatum give such robust results? Do the
interneurons or the oligodendrocytes
generated provide trophic support for
residual dopaminergic fibers or, as Martı´-
nez-Cerden˜o et al. hypothesize, is the
effect due to the direct electrical impact
of the grafted interneurons on the net-
work? Although one can speculate upon
any number of convoluted circuit rear-
rangements to which the transplanted
MGE cells might contribute, there are
two simple mechanisms by which inhibi-
tion provided by grafted interneurons
could lead to the observed behavioral
changes. Information coming into the
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Figure 1. Modeling the Potential Impact of
Striatum-Grafted MGE Precursors on a Rat
Model of Parkinson’s Disease
(A) A simple diagram of the flow of information
through the medium spiny neurons of the basal
ganglia consisting of the striatum, the external
globus pallidus (GPe), and the internal globus pal-
lidus (GPi), and including themodifying influence of
the subthalamic nucleus (STN). Dopamine input
(orange) is delivered to both the direct and indirect
pathways. The direct pathway leads to a net acti-
vation of the thalamus, whereas the indirect
pathway leads to a net decrease and thus less
motor activity. D1, dopamine type 1 receptor
(excitatory); D2, dopamine type 2 receptor (inhibi-
tory). Black projections indicate excitatory connec-
tions, and blue projections represent inhibitory.
(B) These three panels illustrate how basal ganglia
circuitry is altered in Parkinson’s disease (PD)
(top), and two possible ways by which grafted
GABAergic interneuronscouldhypothetically rescue
proper functionof this network (middle, bottom). The
green cells represent EGFP-positive grafted inter-
neurons and their possible contributions to restora-
tion of basal ganglia network function. Note that
line thickness represents strength of connection.
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nergic neurons of the SNc segregates into
two parallel routes, generally referred to
as the direct and indirect pathways
(Figure 1A). Dopamine is excitatory on
medium spiny neurons of the direct
pathway but inhibitory on those contrib-
uting to the indirect pathway. Because of
this distinction, as well as the differential
involvement of other inhibitory and excit-
atory elements in the two pathways, acti-
vation of the direct pathway results in
increased thalamic and hence motor
activity, whereas activation of the indirect
pathway decreases it. In PD, the direct
pathway is less excited whereas the
indirect one is less inhibited and as
a result the output of the internal globus
pallidus (GPi) onto the thalamus is
increased overall (Figure 1B, top). This
elevation in activity ultimately culminates
in the rigidity and constraint in voluntary
movement characteristically observed in
PD patients.
Because the transplanted MGE neu-
rons alleviate the motor symptoms of
PD animals, their net effect must be to
decrease the inhibitory output of the
GPi to the thalamus. This result could
be accomplished either by preferentially
inhibiting the indirect pathway (Fig-
ure 1B, middle), and thus increasing GPi
inhibitory output, or by providing indis-
criminate inhibition to both the direct
and indirect pathways (Figure 1B, bot-
tom). For the latter to be effective, one
must imagine that the direct pathway
in conditions of PD already has such
a low level of excitability as to make it
nonfunctional, making its further inhibi-
tion irrelevant.
Although many questions remain unan-
swered, the results of Martı´nez-Cerden˜o
et al. suggest that there might be alterna-
tives not only to the transplantation of
dopaminergic precursors into the brain
but also the general efforts for dopamine
replenishment in PD patients. It is impor-
tant to remember that animal models,
and the behavioral tests used to assayCell Stem Cethem, do not always reproduce human
symptoms and responses. However, if
the approach outlined by Martı´nez-
Cerden˜o and colleagues proves to be
effective, it offers a number of attractive
advantages over the more traditional
transplantation of SNc DA neurons. First
of all, fewer cells are probably needed
for transplantation (i.e., GABAergic inter-
neurons versus SNc cells). Second, the
cells transplanted are of a kind normally
found in the striatum. Finally, the interneu-
rons have been shown to have a remark-
able ability to disperse, integrate, and
persist within the striatum. Thus, it may
be that a minimal impact on GABAergic
activity in the striatum, 5% in the case of
Martı´nez-Cerden˜o et al., is sufficient to
provide an effective therapy for PD.REFERENCES
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